Epistaxis: Detailed Causes and Step-by-Step Management
Causes of Epistaxis
Anatomic Sources
- Anterior epistaxis (95% of cases) originates from Kiesselbach's plexus on the anterior nasal septum, where five arterial systems converge to create a vulnerable vascular network. 1, 2
- Posterior epistaxis (5% of cases) arises from branches of the sphenopalatine artery on the posterior septum (70%) or lateral nasal wall (24%), making it more difficult to control and more likely to cause significant blood loss. 1, 2
Local Causes
- Digital trauma (nose picking) and vigorous nose blowing are major contributors to recurrent anterior epistaxis, particularly in children and elderly patients with dry nasal mucosa. 3
- Nasal trauma accounts for 20% of epistaxis cases, including blunt facial injury and septal fractures. 4, 5
- Nasal infections (rhinosinusitis) cause 18% of cases through mucosal inflammation and hyperemia. 4, 5
- Foreign bodies present with unilateral epistaxis in 7% of pediatric cases and can cause tissue necrosis (especially disk batteries within 3 hours). 1
- Intranasal drug use (cocaine, other inhalants) damages nasal mucosa and increases bleeding frequency. 3
- Nasal corticosteroid sprays increase epistaxis risk 2.7-fold through chronic mucosal irritation. 3
Systemic Causes
- Hypertension is present in 39% of epistaxis patients, though whether it directly causes bleeding or simply reflects the stressed state remains debated. 1, 4
- Anticoagulant and antiplatelet medications (warfarin, aspirin, clopidogrel, direct oral anticoagulants, NSAIDs) significantly increase bleeding severity and recurrence risk. 3, 6
- Bleeding disorders (von Willebrand disease, hemophilia, thrombocytopenia) must be screened for in patients with easy bruising, prolonged bleeding from minor cuts, or family history. 3
- Hereditary hemorrhagic telangiectasia (HHT) should be suspected in patients with bilateral recurrent nosebleeds, visible nasal/oral telangiectasias, or family history of recurrent epistaxis. 3
- Environmental factors including dry heat, abrupt temperature changes, and low humidity create fragile, hyperemic nasal mucosa that bleeds easily. 3, 7
Rare but Critical Causes
- Juvenile nasopharyngeal angiofibroma presents with unilateral epistaxis in adolescent males and may not be visible on anterior rhinoscopy; delayed diagnosis risks life-threatening bleeding. 1
- Nasal malignancy must be excluded in patients with recurrent unilateral epistaxis, particularly in older adults. 1, 3
Step-by-Step Management Algorithm
STEP 1: Initial Assessment and Triage (First 60 Seconds)
Assess for immediate life-threatening features:
- Hemodynamic instability (tachycardia, hypotension, altered mental status) requires immediate IV access, volume resuscitation, and preparation for advanced interventions. 3
- Airway compromise from blood in the oropharynx mandates urgent airway protection. 3
- Active bleeding with hemodynamic instability, airway compromise, or bleeding duration >30 minutes in 24 hours defines severe epistaxis requiring prompt escalation. 3
Position the patient correctly:
- Seat the patient upright with head tilted slightly forward to prevent blood from flowing into the airway or stomach. 3
- Instruct the patient to breathe through the mouth and spit out blood rather than swallow it to reduce aspiration risk and allow accurate assessment of blood loss. 3
Obtain baseline vital signs:
- Measure blood pressure immediately because approximately 33% of epistaxis patients have undiagnosed hypertension, which may influence vasoconstrictor selection and overall management. 3
STEP 2: First-Line Mechanical Hemostasis (0-15 Minutes)
Apply direct nasal compression:
- Apply firm, continuous pressure to the soft lower third of the nose for a full 10-15 minutes without intermittent checking; premature release is the most common cause of treatment failure. 3
- Compression alone resolves the vast majority of anterior epistaxis cases and should be performed by the patient, caregiver, or clinician. 3
If bleeding persists after 15 minutes of proper compression, proceed to STEP 3.
STEP 3: Topical Vasoconstrictor Application (15-30 Minutes)
Prepare the nasal cavity:
- Clear the nasal cavity of blood clots by suction or gentle nose blowing to allow visualization and vasoconstrictor contact with the bleeding site. 3
Apply topical vasoconstrictor:
- Spray oxymetazoline or phenylephrine (2 sprays into the bleeding nostril) and resume firm compression for another 5-10 minutes; this stops bleeding in 65-75% of emergency department cases. 3
- Before using vasoconstrictors, verify baseline blood pressure is documented because these agents carry increased risk of cardiac or systemic complications in hypertensive or cardiovascular-compromised patients. 3
If bleeding persists after 15-30 minutes of compression plus vasoconstrictors, proceed to STEP 4.
STEP 4: Identify the Bleeding Source
Perform anterior rhinoscopy:
- After clot removal, perform anterior rhinoscopy to identify the bleeding source, which is most often Kiesselbach's plexus on the anterior septum. 3
Escalate to nasal endoscopy if:
- Anterior rhinoscopy fails to identify the source, or
- Bleeding is difficult to control, or
- Recurrent bleeding occurs despite prior treatment, or
- Concern exists for unrecognized pathology (unilateral recurrent bleeding, suspected mass, foreign body). 1, 3
- Nasal endoscopy localizes the bleeding site in 87-93% of cases and is essential for posterior epistaxis. 1, 3
STEP 5: Definitive Treatment Based on Identified Source
If a focal anterior bleeding point is identified:
Cauterization:
- Anesthetize the identified bleeding site with topical lidocaine or tetracaine before cautery to improve patient comfort and procedural success. 3
- Cauterize only the active bleeding point; limit application strictly to avoid excessive mucosal injury. 1, 3
- Avoid bilateral simultaneous septal cautery because it markedly increases the risk of septal perforation. 1, 3
- Electrocautery is more effective than chemical cauterization, with recurrence rates of 14.5% versus 35.1%. 3
Post-cautery prevention:
- Apply petroleum jelly or nasal saline gel to the nasal mucosa 2-3 times daily for at least one week to prevent recurrence. 3, 6
- Use saline nasal sprays frequently throughout the day to keep the nasal mucosa moist. 3
- Recommend a bedside humidifier in dry environments to prevent fragile, hyperemic mucosa. 3
STEP 6: Nasal Packing (If Cautery Fails or Source Not Identified)
Indications for nasal packing:
- Bleeding persists after 15-30 minutes of proper compression combined with vasoconstrictors, or
- Life-threatening hemorrhage is present, or
- A posterior bleeding source is suspected. 3
Selection of packing material:
- For patients on anticoagulants or antiplatelet medications, use ONLY resorbable/absorbable packing materials (Nasopore, Surgicel, Floseal) to minimize trauma during removal. 3, 6
- For patients without bleeding risk factors, either resorbable or non-resorbable materials may be used. 3
Post-packing care:
- Apply saline nasal spray frequently to keep packing moist and promote comfort. 3
- Educate the patient about the type of packing used, timing and plan for removal (or expected resorption), and warning signs requiring immediate reassessment (active bleeding despite packing, fever >38.3°C, vision changes, facial swelling, shortness of breath). 3
Antibiotic prophylaxis:
- The role of prophylactic antibiotics after nasal packing remains uncertain; the AAO-HNS identifies this as a research need without a firm recommendation. 1
STEP 7: Management of Patients on Anticoagulants/Antiplatelets
Do NOT discontinue anticoagulation for non-life-threatening epistaxis:
- Continue anticoagulant and antiplatelet medications and attempt first-line local measures (compression, vasoconstrictors, cautery, packing) BEFORE considering medication withdrawal, transfusion, or reversal agents unless bleeding is life-threatening. 3, 6
- The thrombotic risk from stopping anticoagulation typically outweighs the bleeding risk from minor epistaxis. 6
For life-threatening epistaxis in anticoagulated patients:
| Anticoagulant | Reversal Strategy |
|---|---|
| Warfarin | 4-factor prothrombin complex concentrate (PCC) provides faster INR correction than fresh frozen plasma; add vitamin K. [3] |
| Apixaban, rivaroxaban, edoxaban | Andexanet alfa (400 mg IV bolus over 15 min, then 480 mg infusion over 2 hours for low-dose; 800 mg bolus over 30 min, then 960 mg over 2 hours for high-dose) OR 2,000 units of 4-factor PCC if andexanet unavailable. [3,6] |
| Dabigatran | Idarucizumab (specific reversal agent) OR 4-factor PCC. [3] |
| Unfractionated heparin/LMWH | Protamine sulfate. [3] |
| Aspirin, clopidogrel, prasugrel, ticagrelor | Platelet transfusion (effectiveness depends on timing of last dose). [3] |
STEP 8: Advanced Interventions for Refractory Bleeding
Indications for specialist referral:
- Persistent bleeding despite appropriate nasal packing, or
- Recurrent bleeding despite correct local treatment and preventive measures, or
- Three failed packing attempts. 3
Surgical and interventional options:
- Endoscopic sphenopalatine artery ligation has a 97% success rate compared to 62% for conventional packing, with recurrence rates <10% versus 50% for packing. 3
- Endovascular embolization has an 80% success rate with recurrence rates <10%, comparable to surgical ligation. 3
- Evaluate candidacy for arterial ligation or embolization when persistent or recurrent bleeding is not controlled by packing or cauterization. 3
STEP 9: Documentation and Follow-Up
Critical documentation elements:
- Record duration of bleeding episode, response to compression, medication history (all anticoagulants, antiplatelets, NSAIDs, nasal corticosteroids, intranasal drugs), personal or family history of bleeding disorders, and blood pressure measurement. 3
- Document outcomes within 30 days for patients treated with non-resorbable packing, surgical arterial ligation, or endovascular embolization to assess for complications and recurrent bleeding. 3
Follow-up requirements:
- Routine follow-up is recommended for all patients who have undergone invasive treatments to assess for complications, recurrent bleeding, and underlying conditions when treatments are ineffective. 1, 3
Special Populations and Scenarios
Elderly Patients (≥75 Years)
- Elderly patients should be triaged urgently because age-related anatomic changes increase the likelihood of posterior sources and complications. 3
- Posterior epistaxis occurs more often in the elderly and is frequently associated with hypertension, atherosclerosis, and conditions that decrease platelets and clotting function. 7
Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
- Screen for HHT in patients with bilateral recurrent nosebleeds or family history by inspecting nasal and oral mucosa for telangiectasias. 3
- Prefer resorbable nasal packing materials for HHT patients because removal of non-resorbable packing can irritate the nasal cavity and increase re-bleeding risk. 3
- Refer HHT patients to an HHT Center of Excellence for comprehensive multidisciplinary management. 3
Pediatric Patients
- Foreign bodies are a common cause in children, presenting with unilateral epistaxis, rhinorrhea, and foul smell; delay in diagnosis can result in nasal infection, sinusitis, septal perforation, or tissue necrosis (disk batteries within 3 hours). 1
Common Pitfalls to Avoid
- Premature release of nasal compression (checking before 10-15 minutes) is the most common cause of treatment failure. 3
- Overlooking underlying pathology in recurrent unilateral epistaxis; consider nasal masses, juvenile nasopharyngeal angiofibroma, or malignancy. 1, 3
- Bilateral simultaneous septal cautery markedly increases the risk of septal perforation. 1, 3
- Using non-resorbable packing in patients on anticoagulants or antiplatelets increases trauma during removal and re-bleeding risk. 3, 6
- Discontinuing anticoagulation prematurely for non-life-threatening epistaxis; the thrombotic risk typically outweighs the bleeding risk. 3, 6
- Stopping aspirin in high-risk cardiovascular patients (recent MI, stents); survival benefits outweigh bleeding risks. 3
- Neglecting prevention (nasal moisturization, humidification) leads to recurrent episodes. 3
- Delaying endoscopic evaluation after multiple packing failures; prompt endoscopy excludes underlying pathology. 3
- Routinely lowering systemic blood pressure during acute nosebleeds; excessive reduction may precipitate renal, cerebral, or coronary ischemia. 3
Patient Education for Prevention
- Avoid digital trauma (nose picking) and vigorous nose blowing for at least 7-10 days after treatment. 3, 5
- Apply petroleum jelly or nasal saline gel to the anterior nasal mucosa 2-3 times daily to maintain moisture. 3, 6
- Use saline nasal sprays frequently throughout the day. 3
- Place a bedside humidifier in dry environments. 3
- Avoid strenuous activity, heavy lifting, and placing tissues/cotton in the nose for at least 7 days after packing removal. 6
- Consider stopping nasal corticosteroids in patients with recurrent or severe epistaxis due to the 2.7-fold increased bleeding risk. 3